Skip to the stories
Wednesday, 4 November 2026
Saved

Next edition

1:09

Headlines

Models & Products

Pathos AI raises 237 million dollars in Series E round

Artificial intelligence drug development company Pathos AI has raised 237 million dollars in new funding to support its oncology platform and advance clinical trial programs.

FTMQ SI, written by our newsroom0 views

Share
Picture: SiliconANGLE AI

Artificial intelligence drug development startup Pathos AI Incorporated has secured 237 million dollars in a Series E funding round, SiliconANGLE reported. The round was led by pharmaceutical company Bristol Myers Squibb Company and values Pathos AI at 3 billion dollars. Returning investors whose names were not disclosed also participated in the financing. [1]

According to SiliconANGLE, Pathos AI utilizes an artificial intelligence platform named Foundry to develop cancer therapeutics. The company stated that the platform accesses approximately 200 petabytes of oncological data. Foundry also ingests information that is generated directly by internal drug development programs at Pathos AI. [1]

SiliconANGLE reported that the company possesses an existing roster of major backers. That investor list includes AstraZeneca plc, New Enterprise Associates, and General Atlantic. [1]

Share

In short

  • Pathos AI raised 237 million dollars in a Series E round at a 3 billion dollar valuation.
  • Bristol Myers Squibb led the funding round alongside unnamed returning investors.
  • Pathos AI uses an artificial intelligence platform called Foundry that accesses 200 petabytes of oncological data.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]AI drug development startup Pathos AI closes $237M investmentSiliconANGLE AI, 11d ago (the report this story comes from)

Our newsroom writes these reports with the help of software, from the 1 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Models & Products

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.